(Q42710614)

English

Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation

scientific article published on 19 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 November 2017

Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation (English)

1 reference

Europe PubMed Central

5 November 2017

1 reference

based on heuristic

inferred from title

author name string

Tarek M K Motawi

1

1 reference

Europe PubMed Central

5 November 2017

Yasser Bustanji

2

1 reference

Europe PubMed Central

5 November 2017

Shohda A El-Maraghy

3

1 reference

Europe PubMed Central

5 November 2017

Mutasem O Taha

4

1 reference

Europe PubMed Central

5 November 2017

Mohamed A S Al Ghussein

5

1 reference

Europe PubMed Central

5 November 2017

publication date

19 June 2013

1 reference

Europe PubMed Central

5 November 2017

Journal of Biochemical and Molecular Toxicology

1 reference

Europe PubMed Central

5 November 2017

27

1 reference

Europe PubMed Central

5 November 2017

9

1 reference

Europe PubMed Central

5 November 2017

425-436

1 reference

Europe PubMed Central

5 November 2017

Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Mast cell stabilization: novel medication for obesity and diabetes

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Glycogen synthase kinase-3: properties, functions, and regulation

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

New perspectives into the molecular pathogenesis and treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Sequential phosphorylation of CCAAT enhancer-binding protein beta by MAPK and glycogen synthase kinase 3beta is required for adipogenesis

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation.

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Glycogen synthase kinase 3: an emerging therapeutic target

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Pharmacological inhibitors of glycogen synthase kinase 3.

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Docking-based comparative intermolecular contacts analysis as new 3-D QSAR concept for validating docking studies and in silico screening: NMT and GP inhibitors as case studies

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Renal and hepatic transporter expression in type 2 diabetic rats

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

A role for kinesin in insulin-stimulated GLUT4 glucose transporter translocation in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B.

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

The role of glycogen synthase kinase 3beta in insulin-stimulated glucose metabolism

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Role of resistin in obesity, insulin resistance and Type II diabetes

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Adiponectin, obesity, and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FJBT.21503

21 January 2018

Identifiers

10.1002/JBT.21503

1 reference

Europe PubMed Central

5 November 2017

1 reference

Europe PubMed Central

5 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42710614&oldid=1967069452"